Expansion of PMx Commercialization Partnership

Diaceutics

17/07/2025 07:00

RNS Number : 3842R

Diaceutics PLC

17 July 2025

 

Diaceutics PLC

 

Diaceutics Expands PMx Commercialization Partnership Following Early Success

New York, Belfast and London, 17 July 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces the expansion of its PMx commercialization partnership contract. This development follows early success in the collaboration, which was initiated only three months ago, and reflects our partner's decision to broaden the scope of services delivered under the agreement.

Ryan Keeling, Chief Executive Officer at Diaceutics, commented: "This expansion is a testament to the tangible value our PMx solution delivers. It reflects our partner's confidence in the solution and their commitment to scaling impact through deeper collaboration. We're proud to be advancing our mission of getting every patient the right test and the right treatment at the right time."

The expanded agreement is expected to contribute incremental service revenue in FY2025 and further strengthens Diaceutics' position as a strategic partner in the precision medicine ecosystem. The enhanced contract introduces an additional PMx service, Signal Connect - designed to support healthcare professionals (HCPs) in deepening awareness and increasing clinical actionability. Signal Connect combines our groundbreaking DXRX signal data alerts with expert direct-to-physician engagement services. This service is particularly impactful in cases involving rare or novel biomarkers, where timely identification and education are critical to therapeutic consideration and access to life-changing targeted therapies.

The PMx solution, which integrates multiple services into a single, multi-year engagement, continues to demonstrate its value as a precision commercialization solution for biopharma companies. By enabling lean, agile launches and maximizing patient discovery, PMx delivers commercial impact which Diaceutics believes to be at with a third of the cost of traditional commercialization.

Enquiries: 

Diaceutics PLC
Ryan Keeling,Chief Executive Officer
Nick Roberts, Chief Financial Officer
Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com
Canaccord Genuity Limited (Nomad & Broker)
Tel: +44 (0)20 7523 8000
Simon Bridges, Andrew Potts, Harry Rees


 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

 

About Reach Announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRARFMRTMTIBBTA